Liver Enzymes
Biological origins, routine metabolic panel measurement, clinical interpretation, and limitations of serum transaminases and biliary enzymes.
ALT and AST are enzymes that leak into your bloodstream when liver cells are irritated or injured, while ALP and GGT point more toward bile duct stress. Here's the catch that trips up too many people (and doctors): thousands of patients with serious MASH scarring have 'normal' ALT and AST numbers on their lab printout, especially because lab 'normal' ranges vary widely. Elevated enzymes are a clear flag to investigate, but normal enzymes never give an automatic all-clear.
What Are Liver Enzymes?
- AST, ALT, ALP, and GGT participate in amino acid metabolism, bile production, and detoxification1,2
- Can be found in multiple locations in the body2
How Are They Measured?
- Liver enzyme levels are measured through liver function tests which are performed using a blood sample4
- Part of hepatic/comprehensive metabolic panels offered at many laboratories across the globe2,4,5
Use in MASLD/MASH Care
- Liver enzymes provide a broad indication of liver health2
- Elevated ALT, AST, and GGT are common in patients with MASLD and can help identify at-risk individuals for further evaluation6-8
Strengths
- Liver enzymes have multiple uses including screening, diagnosis, and monitoring of patients with a variety of liver diseases4
- Liver enzymes can be tested individually or as part of a panel4,5
- Included in routine laboratory tests4
Limitations
- Normal levels do not necessarily rule out MASH7
- Reference range differences affect interpretation2
Key Liver Enzymes, Tissues of Origin, and Clinical Significance
| Enzyme | Tissue(s) of Origin | Clinical Significance |
|---|---|---|
| ALT | Mainly hepatocytes, but is also present in cardiac, renal, and muscle tissue2 | High: Liver damage3 ALT is the most sensitive indicator of liver injury due to its predominant expression in the liver3 |
| AST | Hepatocytes, cardiac, muscle, renal, and brain tissue2,3 | High: Nonspecific marker of liver injury3 |
| ALP | Hepatobiliary tract, bone, placenta, intestines2 | High: Bile duct disease2 |
| GGT | Mainly hepatobiliary tract; present in multiple other organs (unspecific)2 | High: Hepatobiliary disease2 |
Biological Healthy ALT Upper Limits vs. Commercial Lab Ranges (Adult & Pediatric)
| Population | Healthy Biological ULN | Typical Lab Report Ceiling | Guideline Action Threshold |
|---|---|---|---|
| Adult Men (≥18 y) | 29–33 U/L9,10 | 40–55 U/L | Persistently >30 U/L with cardiometabolic risk warrants FIB-4 calculation and secondary liver workup8,10 |
| Adult Women (≥18 y) | 19–25 U/L9,10 | 35–45 U/L | Persistently >20–25 U/L with cardiometabolic risk warrants FIB-4 calculation and secondary liver workup8,10 |
| Pediatric Boys (9–17 y) NASPGHAN / AAP11 |
25 U/L11 | 40–50 U/L (adult-derived) | ≥50 U/L (≥2× ULN) for ≥3 months, or any single ALT ≥80 U/L → full pediatric MASLD & competing-disease evaluation (do not use FIB-4)11 |
| Pediatric Girls (9–17 y) NASPGHAN / AAP11 |
22 U/L11 | 35–45 U/L (adult-derived) | ≥44 U/L (≥2× ULN) for ≥3 months, or any single ALT ≥80 U/L → full pediatric MASLD & competing-disease evaluation (do not use FIB-4)11 |